CD8A and neoplasm: An immune-histochemical primary tumor analysis in patients bearing wild type k-ras (k-ras/wt) (22 cases) or activating K-ras mutations (K-ras/mut) (19 cases) prior vaccination, revealed no significant difference concerning TS expression (score of expression: 30 for overall, 28 for K-ras/wt and 33 for K-ras/mut ) (Figure 1A) and tumor infiltration by CD4+, CD8+, CCR7+ T cells and Tregs (Figure 1B).